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Abstract: Although the varying phenotypic spectra of hypertensive heart disease (HHD) can be assessed
by electrocardiography (ECG), echocardiography and cardiovascular magnetic resonance (CMR), ECG
criteria for left ventricular hypertrophy (LVH) are insensitive, while echocardiography and CMR are
expensive, less readily available and often lack requisite expertise. Consequently, the use of circulating
biomarkers in the diagnosis and prognostication of HHD beyond the traditional N-terminal pro- b-type
natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) have become an attractive alter-
native. We carried out a PubMed and Google Scholar databases’ search of original articles on circulating
biomarkers used in the diagnosis of the different spectrum of HHD over the last 10 years [2005–2015] in
humans. Fourteen studies met the inclusion criteria with NT-pro BNP being the most studied circulat-
ing biomarker in HHD followed by soluble ST2 (sST2). There is a lack of data on the use of circulating
biomarkers in HHD. There is a need to explore further this area of investigative cardiology.
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Introduction 
Hypertension (HT) is the leading single risk factor for 
cardiovascular events and deaths worldwide (1). It is 
projected that the total number of people affected by HT 
will increase to about 1.56 billion in 2025 (2) Sub-Saharan 
Africa (SSA) is particularly affected by this epidemic, and 
will witness the greatest increase in disease burden (2). The 
consequences of HT vary from congestive cardiac failure, 
chronic kidney disease, cerebrovascular accidents, vascular 
dementia, cardiovascular mortality and sudden death (3-5).
One of the main complications of HT is hypertensive 
heart disease (HHD), representing the accumulation of 
structural and functional adaptations to increased blood 
pressure load on the heart (6). Features of this condition 
are left ventricular hypertrophy (LVH), increased vascular 
and ventricular stiffness and impaired LV filling which 
ultimately lead to heart failure, if not adequately treated (6).
Although LVH can be assessed by electrocardiography 
(ECG) and echocardiography, ECG criteria for LVH 
generally have low sensitivity even though there have been 
some improvements in its diagnostic accuracy especially in 
obesity (7). On the other hand echocardiography results may 
be of poor quality, and more so in patients with obesity or 
pulmonary disease (8,9) This has led to accelerated research 
on the use of circulating biomarkers to assist as diagnostic and 
prognostic tools in HHD apart from the traditional biomarkers 
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like B-type natriuretic peptide (BNP) and N-terminal pro- 
b-type natriuretic peptide (NT-proBNP) (10).
Search strategy
This literature review followed all the guidelines set out 
by the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) statement for articles 
of this nature. In order to ensure a comprehensive and 
current appraisal of the use of circulating biomarkers in the 
spectrum of HHD we considered articles on human studies 
published between 2005 and 2015. We excluded all studies 
which focused on HT as a secondary factor and not as a 
primary factor. We reviewed the abstracts of all potentially 
relevant paper while full articles were accessed through 
PubMed and Google Scholar. There was careful scrutiny 
of the references of all the relevant research articles for 
possible additional data sources while the full texts of these 
studies were then similarly accessed.
We also carried out an exploration of bibliographies 
cited in the identified articles to provide further studies. 
We obtained full texts of the articles from various online 
sources. And we used a data extraction sheet to collect the 
information on year of publication, the primary disease 
condition studied, and the circulating biomarker used.
Figure 1 shows the schematic diagram of how the process 
of choosing the studies that were included in the review 
was carried out. Twenty-eight studies on the use of BNP 
or NT-ProBNP, soluble ST2 (sST2) and cardiotrophin-1 
in the diagnosis of the spectrum of HHD were identified 
by PubMed. We excluded four studies on diabetes mellitus, 
another four studies on coronary artery disease, two studies 
on renal disease and one study on obesity, hypertrophic 
cardiomyopathy and pregnancy, respectively. 
NT-ProBNP in HHD
LVH has been reported as one of the conditions in which 
plasma BNP and NT-ProBNP significantly exceed the 
normal range (11). Plasma NT-ProBNP level has been 
found has been found to rise progressively with increasing 
severity of HT particularly when VH is present (11). and 
to be a useful marker of LVH. In a similar way, it has been 
shown that plasma BNP and NT-ProBNP levels are useful 
to differentiate between patients with different spectrum 
of cardiac remodelling (12), and should be considered 
as screening tools to select hypertensive patients that 
should undergo a detailed echocardiographic examination. 
Furthermore, in a recent study, NT-proBNP was found 
to be an independent predictor of survival in hypertensive 
patients and increased LV mass (11). Other workers have 
however found that even though NT-ProBNP is useful 
in differentiating hypertensive patients with or without 
LVH from hypertensive heart failure (HHF), it is not the 
best marker for differentiating hypertensive subjects with 
LVH from those without LVH (13,14). Our group has 
corroborated these observations;(14); among 210 black 
African hypertensive subjects (83 hypertensives without 
LVH, 50 hypertensives with LVH and 77 HHF subjects). In 
of NT-ProBNP compared to hypertensive subjects with or 
without LVH (P<0.002). There was, however, no difference 
in the levels of NT-ProBNP between hypertensive subjects 
with LVH and those without LVH (Figure 2). And similar to 
a previous study (15), NT-ProBNP did not correlate with 
LV mass index, interventricular septal wall thickness and LV 
posterior diastolic wall thickness. We however found that 
NT-ProBNP correlated significantly with mean arterial 
pressure, pulse pressure and age, supporting previous 
studies (16,17) with renal impairment (18).
Novel Biomarkers in HHD 
The limitation of NT-ProBNP in differentiating the various 
spectra of HHD has led to research for the discovery of 
biomarkers of superior usefulness for the clinical handling 
of HT evolving to HHD and HHF (19). A number of 
the biochemical markers that have been studied include 
cardiotrophin-1, ST2, annexin A5, carboxy-terminal pro-
peptide of pro collagen type 1, matrix metalloproteinase-1 
Figure 1 Flow chart of study section.
Total initial identified studies =28
Included studies =14
Diabetes mellitus =4
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(MMP-1) and galectin-3. ST2 and cardiotrophin-1 are 
more frequently studied in cardiovascular disease (CVD) 
compared to the rest.
Cardiotrophin-1
Cardiotrophin-1 appears to be one of the most promising 
biomarkers for criteria which includes relationship between 
its expression in the myocardium and its level in the blood, 
a positive gradient from its concentration in coronary 
sinus blood towards its concentration in peripheral veins, 
association between the concentration in the blood with 
cardiac structural and functional parameters and variation 
of levels of the biomarker with cardiac structural and 
functional changes induced by pharmacological therapy (19). 
Cardiotrophin-1 is a cytokine member of the interleukin-6 
super family, which is produced by cardiomyocytes and 
cardiac fibroblasts in situations of biochemical stress and 
under exposure to humoral factors such as angiotensin-
II (20,21). Once secreted, it interacts with its receptor, 
which is a heterodimer formed by glycoprotein-130 and 
the leukaemia inhibitory factor receptor activating different 
signalling pathways thereby leading to cardiomyocyte growth 
dysfunction (22). Plasma cardiotrophin-1 concentration 
has been found to be increased in hypertensive patients as a 
whole group, compared to normotensive subjects (23,24). It 
has also been reported that plasma cardiotrophin-1 is higher 
in patients with LVH than in patients without LVH (25), and 
in patients with heart failure than in patients with LVH (26). 
In addition, it has been found out that 31% of hypertensive 
patients without LVH already exhibited concentrations of 
cardiotrophin-1 abnormally elevated above the upper normal 
limit measured in the normotensive control population which 
suggests that cardiotrophin-1 increases early in the evolution 
of arterial HT (27). An association exists between anti-
hypertensive-induced decrease of plasma cardiotrophin-1 
and reduction of LV mass index in patients with LVH (28). 
Abnormally high plasma cardiotrophin-1 concentration is 
associated with reduced fractional shortening and altered 
relaxation in patients with inappropriate LV mass (29). 
Lastly, cardiotrophin-1 presents an acceptable sensitivity of 
70% and specificity of 75% to detect LVH, as assessed by 
echocardiography in hypertensive patients (29).
SST2 
The most recent novel circulating biomarker that has 
been tested in differentiating the various spectrum of 
HHD is sST2. ST2 receptor is a member of the Toll-like/
interleukin-1 receptor family. Research in animal models 
have shown that cytokine IL-33 interacts with ST2 receptors 
in cardiac myocytes, thereby comprising a cardioprotective 
stress-responsive signalling system (19). ST2 exists in 
two forms—transmembrane and soluble forms. sST2 is a 
candidate biomarker in CVD. Mice treated with exogenous 
IL-33 demonstrate reduced hypertrophy, and transgenic 
deletion of ST2 abolishes this potentially adaptive effect, 
thereby resulting in severe myocardial hypertrophy and 
IL-33/ST2 signalling becomes activated and the soluble 
form of ST2 is released into the circulation (Figure 3). sST2 
acts as a decoy receptor, sequestering and inhibiting IL-33 
and this potentially explains why it has been observed that 
 
Mechanistic studies identified ST2 as a gene markedly 
induced in mechanically overloaded cardiac myocytes 
(31,32). sST2 is induced in conditions of myocardial 
overload, such as myocardial infarction, when the 
remaining viable myocardium must bear more stress (31). 
sST2 has been found to be increased in the serum of patients 
one day after acute myocardial infarction (AMI) (32). 
In addition, sST2 levels have been shown to predict 
outcome in patients with heart failure and a change in sST2 
over time is also associated with poorer prognosis (32). 
Although the lung has been shown to have the highest 
expression of sST2 levels (33), potential cellular sources of 
sST2 in the cardiovascular system include endothelial cells 
Figure 2 Box plot comparing NT-proBNP levels in patients with 
HT without VH, to patients with HT with VH, and patients 
with HHF. NT-proBNP, N-terminal pro- b-type natriuretic 
peptide; HT, hypertension; VH, ventricular hypertrophy; HHF, 
hypertensive heart failure. 
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(34,35) and cardiac myocytes (33).
after AMI was carried out in 69 human samples and showed 
that sST2 levels correlated with creatinine kinase and 
correlated inversely with LV ejection fraction (LVEF) (31). 
Two larger studies have demonstrated the prognostic value 
of measuring sST2 in AMI. Aoki et al. (36)  measured sST2 
in 810 patients with AMI in the Thrombolysis In Myocardial 
Infarction (TIMI)-14 and Enoxaparin and TNK-tPA with 
or without Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor 
as Reperfusion Strategy in STEMI(ENTIRE)-TIMI-23 
clinical trials. They demonstrated that baseline levels 
of sST2 were higher in patients who died or developed 
congestive heart failure. sST2 levels were also measured 
in 1,239 patients from the Clopidogrel as Adjunctive 
Reperfusion Therapy Thrombolysis in Myocardial Infarction 
28 (CLARITY-TIMI 28) trial (36). The authors found that 
of cardiovascular mortality and heart failure and combined 
measurement of ST2 and NT-proBNP significantly 
improved prediction of cardiovascular death. Measurement 
of sST2 early after AMI in 100 patients undergoing 
cardiovascular magnetic resonance (CMR) also predicted 
adverse LV functional recovery and remodeling (37). 
In an outpatient study, sST2 levels also reflected right 
ventricular heart size and function, and were an independent 
predictor of one-year mortality in outpatients referred for 
echocardiography (38).
Several other studies have reported similar findings: 
sST2 levels correlated with severity of heart failure, LVEF, 
creatinine clearance, BNP, C-reactive protein, and were 
a predictor of mortality (39-42). Concentrations of sST2 
have also been found to be predictive of mortality in 
dyspnoea patients with and without acutely decompensated 
heat failure (43-46). In addition, cardiac surgery patients 
undergoing coronary artery bypass graft ing with 
cardiopulmonary bypass demonstrate a significant rise in 
sST2 levels 24 h after surgery (47). In conclusion, these 
studies indicate that sST2 has potential to be a predictive 
cardiovascular biomarker in patients with AMI, heart failure 
and dyspnoea, but further studies are required.
SST2 as a novel biomarker in HHD 
In spite of the use of sST2 as a marker in the field of 
cardiovascular medicine, there are very few studies on the 
use of sST2 in HHD (48,49). We could demonstrate in our 
laboratory in a sample of 210 black hypertensive patients 
that sST2 differentiates the various stages of HHD, with 
heart failure patients having higher concentrations of sST2 
compared to hypertensive patients with LVH (P<0.001) or 
without LVH (P<0.0001), and patients with HT and LVH 
having higher concentration of sST2 compared to those 
without LVH (Figure 3
of differentiating HT without LVH from hypertensive 
heart failure were 76.5% and 100%, respectively, with 
a cut-off value of 38.01 ng/mL while the sensitivity and 
specificity of distinguishing HT with LVH from HHF 
were 82.4% and 100%, respectively, with a cut-off value 
of 24.97 ng/mL. On the other hand, the sensitivity and 
LVH were 87% and 56%, respectively, with a cut-off value 
of 14.45 ng/mL. We also found pulse pressure, LV internal 
diameter in systole, LV mass indexed for height and LVEF 
to be independent co-variants of sST2 concentrations. We 
concluded in our study as depicted in Figures 3,4 that sST2 
is a better biomarker when compared to NT-ProBNP in this 
regard. We also found in a cohort of 133 patients without 
heart failure that sST2 was not only higher in those with 
LVH compared with those without LVH (23.0±8.33 ng/mL 
versus 14.5±4.9 ng/mL, P<0.001), but patients with 
concentric hypertrophy had the highest concentration 
of sST2 compared to normal geometry, concentric 
remodelling and eccentric hypertrophy (51).
Other less studied novel biomarkers in CVD
Annexin A5
Annexin A5 is a 32-35KDa calcium binding protein that 
Figure 3 Box plot comparing soluble ST2 levels in patients with 
HT, to patients with HT with LVH, and patients with HHF. HT, 
hypertension; VH, ventricular hypertrophy; LVH, left ventricular 
hypertrophy; HHF, hypertensive heart failure.
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becomes upregulated in response to apoptosis (52,53). The 
expression of annexin A5 has been found to be abnormally 
increased in the myocardium of hypertensive patients with 
LVH exhibiting increased apoptosis of cardiomyocytes (54), 
suggesting its potential as biomarker in monitoring the 
progression of HT to HHF. The pathway of the secretion 
and action of annexin A5 is closely related to the pathway of 
cardiotrophin-1.
Carboxy-terminal propeptide of procollagen type I 
Carboxy-terminal propeptide of procollagen type 1 is a 
peptide that is cleaved from procollagen type I during the 
extracellular synthesis of fibril-forming collagen type I 
carboxy-terminal proteinase. It is, therefore, a biochemical 
marker related to the collagen matrix. It has been found to 
be associated with volume of myocardial tissue occupied 
with LVH (55) and hypertensive LVH in human subjects 
(56,57). It has also been shown that serum carboxy-
terminal propeptide procollagen type I is elevated in 
hypertensive patients when compared with normotensive 
subjects (58,59), but no significant differences in the 
levels between hypertensive patients with or without 
LVH similar to our finding using NT-proBNP as the 
biomarker. However, higher concentrations of carboxy-
terminal propeptide procollagen type I have been found 
in hypertensive heart failure when compared with 
hypertensive LVH (60). 
Ratio of MMP-1/tissue inhibitor of 
metalloproteinases-1 (TIMP-1)
The interaction between MMP-1 that initiates the 
degradation of collagen fibres within the heart and its 
TIMP-1 has been found to hold some promise in assessing 
HHD. The ratio of MMP-1/TIMP-1 has been found to be 
abnormally increased in subjects with HHF and abnormally 
decreased in patients with HT with or without LVH (61,62). 
This ratio is higher in hypertensive patients with systolic 
heart failure than in patients with diastolic heart failure. 
Therefore, it is suggested that the determination of MMP-1 
and TIMP-1 in serum might be a useful biochemical 
marker of systolic deterioration and geometric dilatation of 
by the study of Maharaj et al. in the study of 82 subjects 
of African descent with HT (41 with LVEF 50% and the 
other 41 with LVEF <50%) who showed that TIMPI-1, 
MMP-1 and the ratio of MMP-1/TIMPI-1 were higher in 
the subjects with reduced LVEF compared to those with 
normal LVEF (64).
Galectin-3
Galectin-3 is beta-galactoside-binding lectin which is 
expressed by activated macrophages, and involved in 
numerous pathological processes including inflammation, 
fibrosis and tumour growth (65). In heart failure- 
prone animals, galactin-3 is markedly up regulated in 
decompensated heart failure and increased galectin-3 
expression induces cardiac fibroblasts to proliferate and 
deposit type I collagen, thereby contributing to myocardial 
fibrosis and adverse remodeling (66). These findings 
have made galectin-3 to be linked in the development of 
heart failure (66). A recent study shows that the levels of 
galectin-3 are higher in patients with both HT and diabetes 
compared with those with HT or diabetes alone. These 
levels also correlated with LV mass (67).
Discussion
Clinical implications of circulating biomarkers for the 
management of HHD 
The effectiveness of a novel biomarker in clinical practice 
depends on the consistency and strength of the association 
between the candidate biochemical marker for a given 
disease, the consistency and strength of the association 
between the biochemical marker and the outcome of the 
disease, and the extent to which it is an improvement on 
Figure 4 Schematic diagram comparing cardiac blood biomarkers 
soluble ST2 and NT-ProBNP in hypertensive heart disease. 
Soluble ST2, but not NT-ProBNP, may distinguish HT from 
HT with LVH (HTLVH) and absent heart failure. NT-proBNP, 
N-terminal pro- b-type natriuretic peptide; HT, hypertension; 
VH, ventricular hypertrophy; LVH, left ventricular hypertrophy; 
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either adding or replacing established conventional markers 
like NT-ProBNP.
not only complement NT- proBNP but performs better in 
differentiating the different spectra of HT and HHD has set 
the stage for larger clinical trials wherein sST2’s role could 
be demonstrated as superior biomarker when compared 
with NT-ProBNP in the early detection of hypertensive 
patients at risk of developing LVH, identification of 
hypertensive patients with LV prone to evolve to heart 
failure and identification of hypertensive patients with 
HF that will exhibit progressive deterioration of cardiac 
performance. The importance of this type of biomarker 
that will help in the early detection of the complication of 
HT cannot be over emphasized. In SSA, understanding 
the progression of HT to HHD and early detection of this 
process is critical to minimizing CVD in this region (68,69). 
An important test performance for early detection can be 
achieved in this region with limited resources only as point-
of-care blood (or urine) biomarker test. In addition, such 
point-of-care test would need to be significantly cheaper 
and more broadly available when compared to conventional 
investigations like ECG and echocardiography. In the 
current situation, conventional biomarkers cost about twice 
as much as echocardiography in Nigeria, for example, will 
limit the use of such biomarkers in a population with very 
low health insurance coverage, and where most health 
spending by patients is being “out-of-pocket”.
Conclusions
The importance of a biomarker that differentiates 
uncomplicated cases of HT from those at risk or present 
major cardiac complications cannot be over-emphasized 
in settings like SSA with high burden of HHD (70), where 
imaging modalities such as echocardiography, CT and 
CMR are inaccessible for most of the population. However, 
for such a biomarkers like ST2 to be integrated into clinical 
decision making protocols for hypertensive patients, large 
epidemiological and clinical studies will be required to 
assess the cost-effectiveness of such a marker compared to 
conventional ECG and echocardiography. And finally its 
precision to predict outcomes needs to be scrutinized. 
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